Thyroid hormone receptor alpha (THRA) (THRA)

Thyroid hormone receptor alpha (THRα) is a nuclear receptor that acts as a ligand-activated transcription factor, primarily mediating the biological effects of triiodothyronine (T3) [1]. Encoded by the THRA gene, it is highly expressed in the heart, skeletal muscle, bone, and central nervous system, where it regulates essential processes such as heart rate, basal metabolic rate, and skeletal maturation [2]. Unlike its isoform THRβ, which predominates in the liver, THRα is the primary mediator of thyroid hormone action in the cardiovascular system [3]. Mutations in the THRA gene result in Resistance to Thyroid Hormone alpha (RTHα), a condition characterized by growth retardation, skeletal dysplasia, and bradycardia [4]. In drug development, THRα is often viewed as an "off-target" for metabolic therapies due to the risk of inducing tachycardia and bone loss, leading to a preference for THRβ-selective agonists [5]. However, understanding THRα remains vital for treating thyroid-related developmental disorders and managing systemic thyroid hormone sensitivity [6]. The receptor functions by binding to thyroid response elements (TREs) in the promoters of target genes, recruiting co-activators in the presence of ligand to initiate transcription [1]. Pharmacological modulation of THRα is currently limited to non-selective thyroid hormone replacements, though research into selective modulators continues for specific indications [5].

Other names

TR-alphaNR1A1c-erbA-alphaThyroid hormone receptor alpha 1Thyroid hormone receptor alpha 2

Ligand-dependent transcription factor activation; recruitment of co-activators upon T3 binding and co-repressors in the absence of ligand.